Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway.

Journal of translational medicine - 22 Nov 2024

Huang Zhidong, Lou Kaixin, Qi Mengyang, Wang Jinhui, Li Linwei, Sun Bo, Wang Chen, Zhou Xirui, Chen Debo, Liu Hong

Abstract excerpt

BACKGROUND: Currently, there is a lack of biomarkers to identify breast cancer (BC) patients who would benefit from CDK4/6 inhibitors. This study combined machine learning (ML) algorithms based on transcriptomic data with both in vivo and in vitro experiments to identify therapeutic efficacy-related biomarkers of the CDK4/6 inhibitor ribociclib from the perspective of long non-coding RNA (lncRNA). METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 6

Share to Machine Learning

Share to MAP Kinase Signaling System

Share to Protein Kinase Inhibitors

Share to Purines

Share to RNA, Long Noncoding

Source

Open in PubMed Open full text

Identifiers

PMID: 39574120
DOI: 10.1186/s12967-024-05828-x
PMCID: PMC11583401

Genes

CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway.PMID 39574120Read ↗

Purine and pyrimidine metabolism regulatory gene signature predicts prognosis and immunotherapy efficiency in breast cancerSemantic proximity Read ↗

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA ExplorationSemantic proximity Read ↗

Transcriptomic analysis revealed potential regulatory biomarkers and repurposable drugs for breast cancer treatmentSemantic proximity Read ↗

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunitiesSemantic proximity Read ↗

Systematic identification of pan-cancer single-gene expression biomarkers in drug high-throughput screensSemantic proximity Read ↗

Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine TherapySemantic proximity Read ↗

Discovering novel long non-coding RNA predictors of anticancer drug sensitivity beyond protein-coding genesSemantic proximity Read ↗

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.Semantic proximity Read ↗

Functional genomics for breast cancer drug target discoverySemantic proximity Read ↗

CKS1B as Drug Resistance-Inducing Gene—A Potential Target to Improve Cancer TherapySemantic proximity Read ↗

Predicting Tumor Response to Drugs Based on Gene-expression Biomarkers of Sensitivity Learned From Cancer Cell LinesSemantic proximity Read ↗

S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.